Control of Steroid, Heme, and Carcinogen Metabolism by Nuclear Pregnane X Receptor and Constitutive Androstane Receptor

Total Page:16

File Type:pdf, Size:1020Kb

Control of Steroid, Heme, and Carcinogen Metabolism by Nuclear Pregnane X Receptor and Constitutive Androstane Receptor Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor Wen Xie*†‡, Mei-Fei Yeuh‡§, Anna Radominska-Pandya¶, Simrat P. S. Saini*, Yoichi Negishi*, Bobbie Sue Bottroff†, Geraldine Y. Cabrera†, Robert H. Tukey§, and Ronald M. Evans†ʈ *Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213; †Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037; §Laboratory of Environmental Toxicology, Departments of Chemistry, and Biochemistry and Pharmacology, University of California at San Diego, La Jolla, CA 92093; and ¶Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 Contributed by Ronald M. Evans, December 31, 2002 Through a multiplex promoter spanning 218 kb, the phase II UDP- ogens, estrogen, and thyroxin metabolism. Moreover, activation of glucuronosyltransferase 1A (UGT1) gene encodes at least eight dif- PXR in transgenic mice is sufficient to increase levels of UGT ferently regulated mRNAs whose protein products function as the expression and activity, as well as bilirubin and steroid clearance. principal means to eliminate a vast array of steroids, heme metabo- lites, environmental toxins, and drugs. The orphan nuclear receptors Materials and Methods pregnane X receptor (PXR) and constitutive androstane receptor Animals. The generation of VP-hPXR, hPXR (previously known as (CAR) were originally identified as sensors able to respond to numer- VPSXR and SXR) transgenic mice and PXR null mice has been ous environmentally derived foreign compounds (xenobiotics) to described (8). promote detoxification by phase I cytochrome P450 genes. In this report, we show that both receptors can induce specific UGT1A UGT1A1 Promoter Cloning and Site-Directed Mutagenesis. The hu- isoforms including those involved in estrogen, thyroxin, bilirubin, and man UGT1A1 promoter was amplified by using a BAC clone carcinogen metabolism. Transgenic mice expressing a constitutively containing the entire UGT1 locus template (2). All primers were active form of human PXR show markedly increased UGT activity designed based on the sequence encoding the human UGT1A locus toward steroid, heme, and carcinogens, enhanced bilirubin clearance, published in the National Center for Biotechnology Information as well as massively increased steroid clearance. The ability of PXR and GenBank (accession no. AF297093). Site-directed mutagenesis was constitutive androstane receptor and their ligands to transduce both performed by PCR and confirmed by DNA sequencing. the phase I and phase II adaptive hepatic response defines a unique transcriptional interface that bridges the ingestion and metabolism of DNA-Binding Analysis. Electrophoretic mobility-shift assays environmental compounds to body physiology. (EMSA) were performed by using in vitro-transcribed and -trans- lated protein (TNT, Promega) as described (14). Oligonucleotides Ј he metabolism of steroid hormones, other endogenous com- were: UGT1A1, 5 -CTAACGGTTCATAAAGGGTATTAGGT- 3Ј; UGT1A6, 5Ј-CGAGTAGGTCATAAAGGTCACA-3Ј; and Tpounds, and xenobiotics occurs in the hepatogastrointestinal Ј Ј tract. This catabolic process is mediated by phase I enzymes, such UGT1A6m, 5 -CGAGTAGAACATAAAGAACACA-3 . as the monooxygenase CYP enzymes (1), as well as the phase II ͞ conjugating enzymes, such as UDP-glucuronosyltransferase Plasmid Construction and Transfection. The tk-UGT1A6 DR3-Luc (UGTs), sulfotransferases, and GSTs (2). The UGT 1A (UGT1A) and its mutant variants were generated by insertion of correspond- locus is controlled by 13 promoters (A1–A12), spanning Ͼ200 kb ing annealed oligonucleotides into the tk-Luc vector. The expres- of upstream sequence encoding overlapping but distinct mRNAs sion vectors for hPXR, VP-hPXR, and VP-CAR have been (3). Using UDP-glucuronic acid as a cosubstrate, UGT enzymes described (14). CV-1 cell transfection using N-[1-(2,3-dioleoy- convert a diverse set of lipophilic substances to water-soluble loxy)propyl]-N,N,N-trimethylammonium methylsulfate (Roche glucuronides and function as the principal means to eliminate Biochemicals) and HepG2 cell transfections using Lipofectamine steroids, heme metabolites, environmental toxins, and drugs from Plus (Invitrogen) were carried out as before (14, 15). the body (2). Crigler–Najjar syndrome type I results in a lethal Northern and Western Blot Analysis. accumulation of bilirubin due to a defect in the 1A1 promoter, Total RNA was prepared from liver tissues by using TRIzol reagent (Invitrogen). Northern hy- whereas Gilbert’s disease (7% of the population) is a more mild 1A1 bridization was carried out as described (8). Liver microsomes were promoter defect typified by increased sensitivity to certain drugs prepared and analyzed for UGT1A expression. Western blot pro- like Tylenol (2). files were conducted by using an anti-UGT1A antibody, which Nuclear receptor (NR) pregnane X receptor (PXR, also known recognizes only the UGT1A family of proteins, and an anti- as the steroid and xenobiotic receptor or SXR) and the constitutive UGT1A1 antibody that is specific for UGT1A1. androstane receptor (CAR) were originally shown to act through NR response elements localized in the promoters of the target UGT Analysis. The UGT analysis was similar to that described before CYP3A and CYP2B genes (4–10). Pharmaceutical compounds (16). In brief, mouse liver microsomes were prepared as described such as phenobarbital and rifampicin (RIF) have been reported as (16). The [14C]UDP-GlcUA was used as the sugar donor, and TLC UGT inducers, although the molecular basis remains to be defined was used to separate glucuronidation products. The products were (11, 12). Both phenobarbital and RIF have been empirically used to treat hyperbilirubinemia, a clinical accumulation of serum bili- rubin due to insufficient glucuronidation (11, 13). These com- Abbreviations: CAR, constitutive androstane receptor; PXR, pregnane X receptor; RIF, pounds are activators of PXR and CAR, suggesting a plausible rifampicin; TCPOBOP, 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene; UGT, UDP-glucurono- signaling pathway for UGT transcription. syltransferase; NR, nuclear receptor; EMSA, electrophoretic mobility-shift assay. In this report, we show that both receptors can induce specific ‡W.X. and M.-F.Y. contributed equally to this work. UGT1A isoforms including those specialized for bilirubin, carcin- ʈTo whom correspondence should be addressed. E-mail: [email protected]. 4150–4155 ͉ PNAS ͉ April 1, 2003 ͉ vol. 100 ͉ no. 7 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0438010100 Downloaded by guest on September 26, 2021 MEDICAL SCIENCES Fig. 1. Induction of UGT1A expression and glucuronidation by PXR activation. (A) Liver microsomes were prepared from WT and VP-hPXR transgenic mice and subject to Western blot profiling by using a pan anti-UGT1A antibody and a specific anti-UGT1A1 antibody. (B) Mouse liver total RNAs were subjected to Northern blot analysis. The membranes were probed for UGT1A6, UGT1As, CYP3A11, and GAPDH as a loading control. (C) Induction of UGT1A mRNA by RIF in hPXR transgenic mice. WT or transgenic males were gavaged with a single dose of solvent or RIF (50 mg͞kg) 24 h before death. (D) The parental HepG2 cells or the HepG2-hPXR stable cells were treated with DMSO or 25 ␮M RIF for 24 h and subsequently harvested for Northern blot analysis to detect UGT1A1 mRNA. (E) Glucuronidation activity toward ␤-estradiol. The result is shown as the autoradiograph of a TLC plate. (F) Glucuronidation toward thyroid hormones (rT3 and T4) and xenobiotics (4-nitrophenol and 4-OH-PhIP). Results are presented as fold increase in glucuronidation activity over WTs and represent the mean and standard error. visualized with a Molecular Dynamics Storm 820 PhosphorImager. at 4 p.m. by retroorbital eye bleeding within 1 min of initial Alternatively, silica gel in zones corresponding to the glucuronide disturbance. The 24-h urine was collected by using mouse metabolic bands were visualized by autoradiography, or corresponding areas cages (Nalge). Corticosterone levels in plasma or urine were from control lanes were scraped into scintillation vials, and radio- measured with a Corticosterone [125I]RIA kit from ICN. The activity was measured by liquid scintillation counting. statistical analysis was performed with INSTAT 2.03 software. Bilirubin Clearance. Adult males were given a single does of bilirubin Results (10 mg͞kg body weight). Blood samples were collected in untreated tubes1hafterinjection.Serumwasprepared by centrifugation at Activation of PXR Induces UGT Expression and Glucuronidation in 4,000 rpm for 10 min. Total and conjugated bilirubin levels were Transgenic Mice. The regulatory locus of the UGT1A gene is highly measured by Antech Diagnostic (Lake Success, NY). The statistical complex. It harbors 12 promoters that control the independent analysis was performed with INSTAT 2.03 software. expression of a specific UGT isoform with distinctive substrate specificity (2). The isoforms vary at the amino terminus and Blood and Urine Collection and Hormone Analysis. Mouse blood share a common body coded by exons 2–5. For example, the 1A1 samples were collected in EDTA-coated tubes (Becton Dickinson) isoform metabolizes estrogens but not androgens or other Xie et al. PNAS ͉ April 1, 2003 ͉ vol. 100 ͉ no. 7 ͉ 4151 Downloaded by guest on September 26, 2021 Fig. 2. Cloning of the UGT1A1
Recommended publications
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • An Unexpected Target for Androgen Deprivation Therapy with Prognosis and Diagnostic Implications
    Author Manuscript Published OnlineFirst on October 11, 2013; DOI: 10.1158/0008-5472.CAN-13-1462 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Androgen glucuronidation: an unexpected target for androgen deprivation therapy with prognosis and diagnostic implications. Laurent Grosse1, Sophie Pâquet1, Patrick Caron1, Ladan Fazli2, Paul S. Rennie2, Alain Bélanger3 and Olivier Barbier1 1Laboratory of Molecular Pharmacology, CHU-Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, Canada 2 Vancouver Prostate Centre at VGH, University of British Columbia, Vancouver, British Columbia, Canada. 3CHU-Québec Research Centre and Faculty of Medicine, Laval University, Québec, Canada Running title: Ablation therapy improves androgen glucuronidation in PCa Keywords: Prostate cancer, androgen ablation therapy, glucuronidation, biomarker, drug target. Financial support: This study was supported by grants from the Canadian Institutes of Health Research (CIHR), the Terry Fox foundation and the Canadian Foundation for Innovation. S. Pâquet is holder of scholarships from CIHR and the Fonds pour la Recherche en Santé du Québec (FRSQ). L. Grosse is supported by a scholarship from the Fonds pour l’Enseignement et la Recherche (FER) from the Faculty of Pharmacy, Laval University (Québec). O. Barbier is holder of salary grants from the CIHR (New Investigator Award #MSH95330) and FRSQ (Junior 2 Scholarship). Address correspondence to: Olivier Barbier, Ph.D. Laboratory of Molecular Pharmacology CHU-Québec Research Centre 2705, boulevard Laurier Québec (QC) G1V 4G2, Canada Phone: 418 654 2296 Fax: 418 654 2769 Email: [email protected] Conflict of interests: Authors have nothing to disclose. Downloaded from cancerres.aacrjournals.org on September 26, 2021.
    [Show full text]
  • Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
    PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28
    [Show full text]
  • Receptor Af®Nity and Potency of Non-Steroidal Antiandrogens: Translation of Preclinical ®Ndings Into Clinical Activity
    Prostate Cancer and Prostatic Diseases (1998) 1, 307±314 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pcan Review Receptor af®nity and potency of non-steroidal antiandrogens: translation of preclinical ®ndings into clinical activity GJCM Kolvenbag1, BJA Furr2 & GRP Blackledge3 1Medical Affairs, Zeneca Pharmaceuticals, Wilmington, DE, USA; 2Therapeutic Research Department, and 3Medical Research Department, Zeneca Pharmaceuticals, Alderley Park, Maccles®eld, Cheshire, UK The non-steroidal antiandrogens ¯utamide (Eulexin1), nilutamide (Anandron1) and bicalutamide (Casodex1) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5a-DHT has higher binding af®nity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an af®nity two to four times higher than 2-hydroxy¯utamide, the active metabolite of ¯utamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhi- bits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than ¯utamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival bene®ts of ¯utamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival bene®ts, including those comparing ¯utamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone.
    [Show full text]
  • Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation
    1521-009X/46/2/100–108$25.00 https://doi.org/10.1124/dmd.117.076745 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:100–108, February 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation Michael Z. Liao, Chunying Gao, Brian R. Phillips, Naveen K. Neradugomma, Lyrialle W. Han, Deepak Kumar Bhatt, Bhagwat Prasad, Danny D. Shen, and Qingcheng Mao Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington Received May 5, 2017; accepted November 17, 2017 ABSTRACT Norbuprenorphine (NBUP) is the major active metabolite of bupre- proteomics quantification revealed that hepatic Ugt1a1 and norphine (BUP) that is commonly used to treat opiate addiction Ugt2b1 protein levels in the same amount of total liver membrane ’ ∼ during pregnancy; it possesses 25% of BUP s analgesic activity proteins were significantly increased by 50% in pregnant mice Downloaded from and 10 times BUP’s respiratory depression effect. To optimize versus nonpregnant mice. After scaling to the whole liver with BUP’s dosing regimen during pregnancy with better efficacy and consideration of the increase in liver protein content and liver safety, it is important to understand how pregnancy affects NBUP weight, we found that the amounts of Ugt1a1, Ugt1a10, Ugt2b1, disposition. In this study, we examined the pharmacokinetics of and Ugt2b35 protein in the whole liver of pregnant mice were NBUP in pregnant and nonpregnant mice by administering the significantly increased ∼2-fold compared with nonpregnant mice. same amount of NBUP through retro-orbital injection. We demon- These data suggest that the increased systemic CL of NBUP in dmd.aspetjournals.org strated that the systemic clearance (CL) of NBUP in pregnant mice pregnant mice is likely caused by an induction of hepatic Ugt increased ∼2.5-fold compared with nonpregnant mice.
    [Show full text]
  • Drug Metabolism and Pharmacokinetics (DMPK)
    Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Received; February 25, 2012 Published online; April 27, 2012 Accepted; April 19, 2012 doi; 10.2133/dmpk.DMPK-12-RG-023 Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Salvianolic acid A De-en Hana,b, Yi Zhengb, Xijing Chenb, Jiake Heb, Di Zhaob, Shuoye Yangb, Chunfeng Zhanga*,Zhonglin Yanga,* aState Key laboratory of Natural Products and Functions, China Pharmaceutical University, Ministry of Education, Nanjing, P. R. China. bCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu 210009, China. 1 Copyright C 2012 by the Japanese Society for the Study of Xenobiotics (JSSX) Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Running title:Glucuronidation of salvianolic acid A in Vitro Corresponding Author: Chunfeng Zhang, PhD State Key laboratory of Natural Products and Functions, China Pharmaceutical University 24# Tong Jia Xiang, Nanjing 210009, PR China. E-mail: [email protected] Phone: +86 25 8337 1694 Zhonglin Yang, PhD State Key laboratory of Natural Products and Functions, China Pharmaceutical University 24# Tong Jia Xiang, Nanjing 210009, PR China. E-mail: [email protected] Phone: +86 25 8337 1694 Fax: +86 25 8337 1694 Number of text pages: 23 Number of tables: 2 Number of figures: 6 2 Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE ABSTRACT: Glucuronidation is an important pathway in the elimination of salvianolic acid A (Sal A), however the mechanism of UDP-glucuronosyltransferases (UGTs) in this process remains to be investigated. In this study, the kinetics s of salvianolic acid A glucuronidation by pooled human liver microsomes (HLMs), pooled human intestinal microsomes (HIMs) and 12 recombinant UGTs isozymes were investigated.
    [Show full text]
  • Section 2.6.4 Pharmacokinetics Written Summary EMTRICITABINE
    SECTION 2.6 NONCLINICAL SUMMARY Section 2.6.4 Pharmacokinetics Written Summary EMTRICITABINE/ RILPIVIRINE/ TENOFOVIR DISOPROXIL FUMARATE FIXED-DOSE COMBINATION 17 August 2010 CONFIDENTIAL AND PROPRIETARY INFORMATION Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Section 2.6.4 Pharmacokinetics Written Summary Final TABLE OF CONTENTS SECTION 2.6 NONCLINICAL SUMMARY........................................................................................................1 TABLE OF CONTENTS .......................................................................................................................................2 GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ..............................................................5 2.6. NONCLINICAL SUMMARY.......................................................................................................................8 2.6.4. PHARMACOKINETICS WRITTEN SUMMARY .........................................................................8 2.6.4.1. Brief Summary................................................................................................................8 2.6.4.2. Methods of Analysis .....................................................................................................14 2.6.4.2.1. Emtricitabine............................................................................................14 2.6.4.2.2. Rilpivirine ................................................................................................14 2.6.4.2.3. Tenofovir Disoproxil Fumarate
    [Show full text]
  • Product Monograph Casodex®
    PRODUCT MONOGRAPH Pr CASODEX® bicalutamide tablets 50mg Tablets Non-Steroidal Antiandrogen AstraZeneca Canada Inc. Date of Revision: 1004 Middlegate Road July 13, 2017 Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Control No. 205811 CASODEX® is a registered trademark of AstraZeneca UK Limited, used under license by AstraZeneca Canada Inc. COPYRIGHT 1995-2017 ASTRAZENECA CANADA INC. Page 1 of 32 TABLE OF CONTENTS TABLE OF CONTENTS .........................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION......................................................................3 INDICATIONS AND CLINICAL USE ...........................................................................3 CONTRAINDICATIONS.................................................................................................3 WARNINGS AND PRECAUTIONS ...............................................................................4 ADVERSE REACTIONS .................................................................................................8 DRUG INTERACTIONS ...............................................................................................12 DOSAGE AND ADMINISTRATION ...........................................................................13 OVERDOSAGE..............................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY..........................................................14
    [Show full text]
  • Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes in Vitro
    molecules Article Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes In Vitro Hassan Salhab * , Declan P. Naughton and James Barker School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-Upon-Thames, London KT1 2EE, UK; [email protected] (D.P.N.); [email protected] (J.B.) * Correspondence: [email protected]; Tel.: +44-7984974741; Fax: +44-208-4179000 Abstract: Glucuronidation is a Phase 2 metabolic pathway responsible for the metabolism and excretion of testosterone to a conjugate testosterone glucuronide. Bioavailability and the rate of anabolic steroid testosterone metabolism can be affected upon UGT glucuronidation enzyme alter- ation. However, there is a lack of information about the in vitro potential assessment of UGT2B17 inhibition by salicylic acid. The purpose of this study is to investigate if UGT2B17 enzyme activity is inhibited by salicylic acid. A UGT2B17 assay was developed and validated by HPLC using a C18 reversed phase column (SUPELCO 25 cm × 4.6 mm, 5 µm) at 246 nm using a gradient elution mobile phase system: (A) phosphate buffer (0.01 M) at pH = 3.8, (B) HPLC grade acetonitrile and (C) HPLC grade methanol. The UGT2B17 metabolite (testosterone glucuronide) was quantified using human UGT2B17 supersomes by a validated HPLC method. The type of inhibition was determined by Lineweaver–Burk plots. These were constructed from the in vitro inhibition of salicylic acid at different concentration levels. The UGT2B17 assay showed good linearity (R2 > 0.99), acceptable recovery and accuracy (80–120%), good reproducibility and acceptable inter and intra-assay precision Citation: Salhab, H.; Naughton, D.P.; (<15%), low detection (6.42 and 2.76 µM) and quantitation limit values (19.46 and 8.38 µM) for Barker, J.
    [Show full text]
  • Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective
    Cellular and Molecular Neurobiology (2019) 39:523–537 https://doi.org/10.1007/s10571-018-0618-1 REVIEW PAPER Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective Susana Laura González1,2 · Laurence Meyer3 · María Celeste Raggio2 · Omar Taleb3 · María Florencia Coronel2 · Christine Patte‑Mensah3 · Ayikoe Guy Mensah‑Nyagan3 Received: 16 July 2018 / Accepted: 31 August 2018 / Published online: 5 September 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract In the last decades, an active and stimulating area of research has been devoted to explore the role of neuroactive steroids in pain modulation. Despite challenges, these studies have clearly contributed to unravel the multiple and complex actions and potential mechanisms underlying steroid effects in several experimental conditions that mimic human chronic pain states. Based on the available data, this review focuses mainly on progesterone and its reduced derivative allopregnanolone (also called 3α,5α-tetrahydroprogesterone) which have been shown to prevent or even reverse the complex maladaptive changes and pain behaviors that arise in the nervous system after injury or disease. Because the characterization of new related molecules with improved specificity and enhanced pharmacological profiles may represent a crucial step to develop more efficient steroid-based therapies, we have also discussed the potential of novel synthetic analogs of allopregnanolone as valuable molecules for the treatment of neuropathic pain. Keywords Neurosteroids · Neuroactive steroids · Progesterone · Allopregnanolone · Neuropathic pain · Spinal cord · Dorsal root ganglia · Mitochondria Introduction et al. 2015; Guennoun et al. 2015; McEwen and Kalia 2010; Melcangi et al. 2014; Schumacher et al.
    [Show full text]
  • Allopregnanolone Effects in Women Clinical Studies in Relation to the Menstrual Cycle, Premenstrual Dysphoric Disorder and Oral Contraceptive Use
    Umeå University Medical Dissertations, New Series No 1459 Allopregnanolone effects in women Clinical studies in relation to the menstrual cycle, premenstrual dysphoric disorder and oral contraceptive use Erika Timby Department of Clinical Sciences Obstetrics and Gynecology Umeå 2011 Responsible publisher under Swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7459-316-7 ISSN: 0346-6612 Front cover: Ceramic piece in raku technique by Charlotta Wallinder Elektronisk version tillgänglig på http://umu.diva-portal.org/ Tryck/Printed by: Print & Media, Umeå University Umeå, Sweden 2011 ”Morgon. Och sakerna förbi. Och HOTET som om det aldrig funnits. Hon var inte med barn och andra eftertankar behövdes inte.” Ur Lifsens rot av Sara Lidman Table of Contents Table of Contents i Abstract iii Abbreviations v Enkel sammanfattning på svenska vi Original papers ix Introduction 1 The menstrual cycle 1 Hormonal changes across the menstrual cycle 1 Brain plasticity across the menstrual cycle 2 Premenstrual symptoms and progesterone – a temporal relationship 3 Premenstrual symptoms in the clinic 3 Epidemiology of premenstrual symptoms/PMS/PMDD 3 The symptom diagnoses of PMDD and PMS 5 Comorbidity and risk factors in PMDD 6 Treatment options for PMDD 7 Trying to understand PMDD by in vivo and in vitro research 8 Etiological considerations in PMDD 8 Brain imaging in PMDD patients across the menstrual cycle 9 Connections between the GABA system and PMDD 10 Neurosteroids 12
    [Show full text]
  • Characterisation of Serum Progesterone and Progesterone-Induced Blocking Factor
    www.nature.com/scientificreports OPEN Characterisation of serum progesterone and progesterone- induced blocking factor (PIBF) levels across trimesters in healthy pregnant women Mark Kit Lim1,5*, Chee Wai Ku2,5, Thiam Chye Tan2, Yin Hao Justin Lee1, John Carson Allen3 & Nguan Soon Tan1,4 Progesterone-induced blocking factor (PIBF), which plays an important role in maintaining healthy pregnancies, has shown great promise as a prognostic biomarker for threatened miscarriage. To better characterise the physiological trends of progesterone and PIBF, we analysed serum progesterone and PIBF concentrations in healthy non-pregnant and pregnant women across trimesters. We saw increasing concentrations of progesterone and PIBF in pregnant women with advancing trimesters. The serum progesterone and PIBF percentiles across gestational age in healthy pregnancies can be used as a guide for the formulation of reference ranges. We also demonstrated a signifcant positive correlation between progesterone and PIBF levels. This study demonstrates increasing progesterone and PIBF concentrations in later trimesters and underscores the importance of progesterone and PIBF in healthy pregnancies. Characterisation of progesterone and PIBF across gestational age in healthy pregnant women may help to prognosticate pregnancy viability and support further research into the importance of progesterone and PIBF in the maintenance of healthy pregnancies. Progesterone and progesterone-induced blocking factor (PIBF) are important in the mainte- nance of healthy pregnancies. Progesterone-induced blocking factor (PIBF), a protein comprising of 757 amino acid residues with a predicted molecular mass of 89 kDa, is important in the maintenance of human pregnancy and the progesterone dependent immunomodulation by the mother1. Progesterone has been established to inhibit myometrial contractility, and progesterone withdrawal has been linked to the start of labour2,3.
    [Show full text]